234 related articles for article (PubMed ID: 28893090)
1. An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma.
Raoul JL; Gilabert M; Adhoute X; Edeline J
Expert Opin Pharmacother; 2017 Oct; 18(14):1467-1476. PubMed ID: 28893090
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials of antiangiogenic therapy for hepatocellular carcinoma.
Taketomi A
Int J Clin Oncol; 2016 Apr; 21(2):213-218. PubMed ID: 26899258
[TBL] [Abstract][Full Text] [Related]
3. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).
Pazo-Cid RA; Lanzuela M; Esquerdo G; Pérez-Gracia JL; Antón A; Amigo G; Trufero JM; García-Otín AL; Martín-Duque P
Clin Transl Oncol; 2012 Aug; 14(8):564-74. PubMed ID: 22855137
[TBL] [Abstract][Full Text] [Related]
4. Novel drugs in clinical development for hepatocellular carcinoma.
Waidmann O; Trojan J
Expert Opin Investig Drugs; 2015; 24(8):1075-82. PubMed ID: 26108356
[TBL] [Abstract][Full Text] [Related]
5. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies.
Sun W; Cabrera R
J Gastrointest Cancer; 2018 Jun; 49(2):107-115. PubMed ID: 29453759
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic strategies in hepatocellular carcinoma: current status.
Zacharoulis D; Hatzitheofilou C; Athanasiou E; Zacharoulis S
Expert Rev Anticancer Ther; 2005 Aug; 5(4):645-56. PubMed ID: 16111465
[TBL] [Abstract][Full Text] [Related]
9. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.
Liu S; Du Y; Ma H; Liang Q; Zhu X; Tian J
Cancer Lett; 2019 Jul; 453():74-83. PubMed ID: 30928380
[TBL] [Abstract][Full Text] [Related]
10. The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
Abou-Alfa GK; Venook AP
Lancet Oncol; 2013 Jun; 14(7):e283-8. PubMed ID: 23725711
[TBL] [Abstract][Full Text] [Related]
11. Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications.
Frenette C; Gish R
World J Gastroenterol; 2012 Feb; 18(6):498-506. PubMed ID: 22363115
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.
Llovet JM; Hernandez-Gea V
Clin Cancer Res; 2014 Apr; 20(8):2072-9. PubMed ID: 24589894
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
Oikonomopoulos G; Aravind P; Sarker D
Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview.
Borriello R; Cerrito L; Gasbarrini A; Ponziani FR
Expert Opin Drug Metab Toxicol; 2023; 19(11):785-794. PubMed ID: 37847538
[TBL] [Abstract][Full Text] [Related]
15. Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.
Tanaka S; Arii S
Int J Clin Oncol; 2006 Apr; 11(2):82-9. PubMed ID: 16622743
[TBL] [Abstract][Full Text] [Related]
16. New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?
Woo HY; Yoo SY; Heo J
Expert Opin Pharmacother; 2017 Jan; 18(1):35-44. PubMed ID: 27849399
[TBL] [Abstract][Full Text] [Related]
17. New strategy of antiangiogenic therapy for hepatocellular carcinoma.
Wu XZ
Neoplasma; 2008; 55(6):472-81. PubMed ID: 18999874
[TBL] [Abstract][Full Text] [Related]
18. Systemic therapy for advanced hepatocellular carcinoma: targeted therapies.
Tella SH; Kommalapati A; Mahipal A
Chin Clin Oncol; 2021 Feb; 10(1):10. PubMed ID: 32434345
[TBL] [Abstract][Full Text] [Related]
19. Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
Brizzi MP; Pignataro D; Tampellini M; Scagliotti GV; Di Maio M
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1053-62. PubMed ID: 27548441
[TBL] [Abstract][Full Text] [Related]
20. The Role of Angiogenesis in Hepatocellular Carcinoma.
Morse MA; Sun W; Kim R; He AR; Abada PB; Mynderse M; Finn RS
Clin Cancer Res; 2019 Feb; 25(3):912-920. PubMed ID: 30274981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
